Stock listing
TSX:MBX Microbix Biosystems Inc. Stock
Home listing (TSX) of Microbix Biosystems Inc.
Follow Microbix Biosystems Inc. into a list and get an email when it puts out news.
Share price · TSX:MBX
$0.275 CAD 0.000 (0.0%)
Close on Nov 20, 2026
- Day range
- $0.275 – $0.295 CADNov 20, 2026
- Volume
- 27,858 sharesNov 20, 2026
- Market cap
- $37.67M CADAt the close on Nov 20, 2026 · price × 137.0M shares outstanding
- 52-week range
- $0.210 – $0.325 CADLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $8,013 CADMedian day 17,000 shares · 2 days with no trades · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| TSX:MBX · Home | $0.275 CAD | 0.000 (0.0%) | 27,858 | $0.295 | $0.295 | $0.275 | $0.275 | Close on Nov 20, 2026 |
| OTC:MBXBF | $0.192 USD | -0.014 (-6.8%) | 10,000 | $0.192 | $0.192 | $0.192 | $0.206 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · TSX:MBX · CAD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.275 | 0.000 | 0.0% | $0.295 | $0.295 | $0.275 | 27,858 | |
| $0.275 | -0.020 | -6.8% | $0.290 | $0.290 | $0.270 | 116,771 | |
| $0.295 | +0.005 | +1.7% | $0.290 | $0.295 | $0.275 | 59,100 | |
| $0.290 | -0.005 | -1.7% | $0.295 | $0.295 | $0.290 | 16,000 | |
| $0.295 | 0.000 | 0.0% | $0.295 | $0.295 | $0.295 | 15,000 | |
| $0.295 | 0.000 | 0.0% | $0.295 | $0.295 | $0.295 | 15,000 | |
| $0.295 | -0.010 | -3.3% | $0.305 | $0.310 | $0.295 | 63,595 | |
| $0.305 | +0.020 | +7.0% | $0.305 | $0.305 | $0.305 | 4,150 | |
| $0.285 | 0.000 | 0.0% | $0.285 | $0.285 | $0.285 | 7,500 | |
| $0.285 | -0.005 | -1.7% | $0.300 | $0.300 | $0.285 | 33,400 | |
| $0.290 | 0.000 | 0.0% | $0.290 | $0.290 | $0.280 | 73,000 | |
| $0.290 | -0.010 | -3.3% | $0.290 | $0.300 | $0.290 | 41,250 | |
| $0.300 | +0.010 | +3.4% | $0.310 | $0.310 | $0.300 | 6,700 | |
| $0.290 | -0.010 | -3.3% | $0.300 | $0.310 | $0.290 | 59,091 | |
| $0.300 | +0.010 | +3.4% | $0.295 | $0.300 | $0.295 | 31,087 | |
| $0.290 | 0.000 | 0.0% | $0.295 | $0.295 | $0.290 | 1,000 | |
| $0.290 | -0.015 | -4.9% | $0.295 | $0.295 | $0.290 | 138,013 | |
| $0.305 | -0.010 | -3.2% | $0.305 | $0.305 | $0.305 | 7,032 | |
| $0.315 | -0.005 | -1.6% | $0.310 | $0.320 | $0.310 | 36,318 | |
| $0.320 | 0.000 | 0.0% | $0.320 | $0.320 | $0.320 | 9,600 | |
| $0.320 | 0.000 | 0.0% | $0.320 | $0.320 | $0.320 | 0 | |
| $0.320 | 0.000 | 0.0% | $0.320 | $0.320 | $0.320 | 69,100 | |
| $0.320 | 0.000 | 0.0% | $0.320 | $0.320 | $0.320 | 2,500 | |
| $0.320 | +0.020 | +6.7% | $0.310 | $0.320 | $0.310 | 46,000 | |
| $0.300 | -0.010 | -3.2% | $0.300 | $0.300 | $0.300 | 4,500 | |
| $0.310 | 0.000 | 0.0% | $0.310 | $0.310 | $0.310 | 15,100 | |
| $0.310 | +0.010 | +3.3% | $0.310 | $0.310 | $0.310 | 2,500 | |
| $0.300 | -0.010 | -3.2% | $0.300 | $0.310 | $0.300 | 18,500 | |
| $0.310 | 0.000 | 0.0% | $0.295 | $0.310 | $0.295 | 6,400 | |
| $0.310 | -0.005 | -1.6% | $0.310 | $0.310 | $0.310 | 2,039 | |
| $0.315 | +0.015 | +5.0% | $0.300 | $0.315 | $0.300 | 6,008 | |
| $0.300 | 0.000 | 0.0% | $0.300 | $0.300 | $0.295 | 106,054 | |
| $0.300 | 0.000 | 0.0% | $0.315 | $0.315 | $0.300 | 6,222 | |
| $0.300 | -0.010 | -3.2% | $0.300 | $0.300 | $0.290 | 9,256 | |
| $0.310 | 0.000 | 0.0% | $0.310 | $0.310 | $0.310 | 0 | |
| $0.310 | -0.005 | -1.6% | $0.310 | $0.310 | $0.310 | 15,500 | |
| $0.315 | +0.015 | +5.0% | $0.300 | $0.315 | $0.300 | 28,201 | |
| $0.300 | +0.005 | +1.7% | $0.300 | $0.300 | $0.300 | 20,000 | |
| $0.295 | 0.000 | 0.0% | $0.300 | $0.300 | $0.295 | 2,050 | |
| $0.295 | -0.005 | -1.7% | $0.300 | $0.300 | $0.295 | 24,000 | |
| $0.300 | -0.005 | -1.6% | $0.310 | $0.315 | $0.290 | 46,500 | |
| $0.305 | 0.000 | 0.0% | $0.295 | $0.310 | $0.295 | 7,948 | |
| $0.305 | +0.005 | +1.7% | $0.300 | $0.305 | $0.300 | 1,500 | |
| $0.300 | -0.010 | -3.2% | $0.310 | $0.310 | $0.290 | 28,500 | |
| $0.310 | 0.000 | 0.0% | $0.305 | $0.310 | $0.305 | 4,700 | |
| $0.310 | 0.000 | 0.0% | $0.310 | $0.310 | $0.310 | 15,500 | |
| $0.310 | 0.000 | 0.0% | $0.310 | $0.310 | $0.310 | 19,010 | |
| $0.310 | 0.000 | 0.0% | $0.310 | $0.310 | $0.310 | 8,000 | |
| $0.310 | +0.020 | +6.9% | $0.300 | $0.310 | $0.300 | 27,200 | |
| $0.290 | -0.005 | -1.7% | $0.295 | $0.295 | $0.288 | 43,000 | |
| $0.295 | +0.015 | +5.4% | $0.280 | $0.295 | $0.280 | 43,680 | |
| $0.280 | -0.015 | -5.1% | $0.290 | $0.290 | $0.280 | 70,061 | |
| $0.295 | +0.005 | +1.7% | $0.290 | $0.295 | $0.290 | 15,535 | |
| $0.290 | 0.000 | 0.0% | $0.285 | $0.290 | $0.285 | 42,800 | |
| $0.290 | -0.005 | -1.7% | $0.295 | $0.295 | $0.290 | 8,500 | |
| $0.295 | 0.000 | 0.0% | $0.295 | $0.295 | $0.290 | 28,027 | |
| $0.295 | -0.025 | -7.8% | $0.300 | $0.300 | $0.295 | 24,836 | |
| $0.320 | 0.000 | 0.0% | $0.320 | $0.320 | $0.320 | 5,000 | |
| $0.320 | +0.015 | +4.9% | $0.305 | $0.320 | $0.305 | 9,550 | |
| $0.305 | +0.005 | +1.7% | $0.295 | $0.305 | $0.295 | 21,240 | |
| $0.300 | -0.010 | -3.2% | $0.310 | $0.310 | $0.300 | 37,000 | |
| $0.310 | +0.010 | +3.3% | $0.300 | $0.310 | $0.300 | 47,000 | |
| $0.300 | +0.013 | +4.3% | $0.290 | $0.300 | $0.290 | 18,000 | |
| $0.288 | +0.003 | +0.9% | $0.295 | $0.295 | $0.288 | 10,015 |
- Ticker
- TSX:MBX
- Asset type
- Stock
- Sector
- Health care
- Industry
- Diagnostics & research services
- Exchange
- TSX
- Currency
- CAD
What changed lately
Latest news release · Nov 19, 2026
Microbix Begins Sales of New Product Category
Latest earnings call · Aug 13, 2026
Microbix Biosystems (TSX:MBX) Q3 2026 Earnings Call
Replay and transcript
Latest deck · Nov 17, 2026
Investor Presentation (November 2026)
Investor deck · 28 slides
Latest news
Microbix Begins Sales of New Product Category
Nov 19, 2026
Closed $0.275 (0.0%) on Nov 20, 2026
Microbix Attending & Presenting at EMMD 2026
Nov 2, 2026
Closed $0.29 (-3.3%) on Nov 2, 2026
Microbix Reviews New U.S. Tariffs on Canada
Oct 28, 2026
Closed $0.29 (-4.9%) on Oct 28, 2026
Microbix Presenting at Planet MicroCap Investment Conference
Oct 26, 2026
Closed $0.315 (-1.6%) on Oct 26, 2026
Microbix Attending & Presenting at IPVS 2026
Oct 19, 2026
Closed $0.32 (+6.7%) on Oct 19, 2026
Microbix Making Keynote Presentation at Masters Summit 2026
Oct 8, 2026
Closed $0.31 (-1.6%) on Oct 8, 2026
Microbix Presenting at Cantech Investment Conference
Oct 6, 2026
Closed $0.30 (0.0%) on Oct 6, 2026
Microbix Qualifies as Supplier for Five Major Dx Test-Makers Product Lines for Support of Leading IVD Manufacturers
Sep 9, 2026
Closed $0.295 (+5.4%) on Sep 9, 2026
Microbix Reports Results for Q3 Fiscal 2026
Aug 13, 2026
Closed $0.30 (-6.3%) on Aug 13, 2026
Microbix Schedules Release of Results for Q3 Fiscal 2026
Aug 6, 2026
Closed $0.29 (0.0%) on Aug 6, 2026
Microbix Biosystems Inc. on 6ix
- Sector
- Health care
- Industry
- Diagnostics & research services
- News releases
- 29 in the last 12 months · 199 in all · newest Nov 19, 2026 · oldest 2005
- Calls
- 12 calls with a replay · 12 with a transcript · latest Aug 13, 2026
- Decks
- 11 decks · latest Nov 17, 2026
Where Microbix Biosystems Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| TSX:MBX · Home listing · This page | TSX | Canada | CAD |
| OTC:MBXBF | OTC | United States | USD |
| Cboe Canada:MBX | Cboe Canada | Canada | CAD |
Cash and shares
Jun 30, 2026 · Microbix Biosystems — Investor Presentation (November 2026)
- Shares outstanding
- 137.2 million
Valuation
EV/sales 2.4× against a median of 1.8×: 6th lowest of 10 Diagnostics & research services companies shown. Statements: 4 quarters to Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- $37.23M CAD
- P/E
- Loss
- EV/sales
- 2.4×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 1.6×
- Gross margin
- 45.9%
- Operating margin
- −27.7%
- Net margin
- −31.7%
- Debt to equity
- 0.3×
- Beta vs S&P/TSX Composite
- 0.03
Diagnostics & research services: the 10 companies nearest in size, of 302 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Microbix Biosystems Inc. · TSX:MBX | US$26.27M | US$25.96M | n/a | 2.4× | n/a | 1.6× | −31.7% | 0.3× | 0.03 |
| Abingdon Health PLC · LSE:ABDX | US$28.10M | US$26.11M | n/a | 1.8× | n/a | 3.5× | −19.4% | 0.2× | n/a |
| MedMira Inc. · TSXV:MIR | US$26.91M | US$27.23M | n/a | 105× | n/a | n/a | −808.2% | n/a | 0.29 |
| BIOQUAL, Inc. · OTC:BIOQ | US$26.83M | US$42.28M | n/a | 1.1× | n/a | 0.8× | −11.0% | 1.0× | -0.01 |
| Ikonisys SA · EURONEXT:ALIKO | US$26.75M | US$31.11M | n/a | 20.4× | n/a | 1.3× | −302.8% | 0.3× | n/a |
| Interpace Biosciences, Inc. · OTC:IDXG | US$26.56M | US$23.63M | 1.2× | 0.6× | 21.0× | 1.1× | 58.1% | 0.0× | -0.33 |
| Bioptic Inc. · TPEX:6850 | US$26.10M | US$22.55M | n/a | n/a | n/a | 2.0× | n/a | 0.2× | n/a |
| genOway SA · EURONEXT:ALGEN | US$25.86M | US$38.95M | 25.4× | 1.7× | 8.7× | 1.1× | 4.4% | 0.7× | n/a |
| Orientbio, Inc. · KRX:002630 | US$25.17M | −US$3.29M | 14.6× | −0.1× | −0.8× | 0.5× | 8.1% | 0.0× | n/a |
| Genesystem Co., Ltd. · KRX:363250 | US$24.68M | US$22.48M | n/a | 29.8× | n/a | 2.8× | n/a | 0.2× | n/a |
| Clever Culture Systems Limited · ASX:CC5 | US$24.56M | US$25.41M | n/a | 8.3× | n/a | 4.9× | −48.4% | 0.4× | n/a |
| Median of the others | US$26.33M | US$25.76M | 14.6× | 1.8× | 8.7× | 1.3× | −15.2% | 0.2× | -0.01 |
Forecasts
Analysts' consensus from EODHD, read Nov 20, 2026. Not 6ix's view and not investment advice.
- Price target
- 0.40 CAD · Analysts' mean
- EPS, year to Sep 2026
- -0.010 · 1 analyst
- Revenue, year to Sep 2026
- 11.55M · 1 analyst
Team and board
Officers
| Officer | Role |
|---|---|
| Cameron Groome | CEO, PRESIDENT AND DIRECTOR |
| Jim Currie | CFO |
| Ken Hughes | COO |
| Deborah Honig | Investor Relations |
| Mark Luscher | SVP, SCIENTIFIC AFFAIRS |
| Phil Casselli | SVP BUSINESS DEVELOPMENT, SALES AND MARKETING |
Board
| Director | Role |
|---|---|
| Martin Marino | CHAIRMAN OF THE BOARD |
| Cameron Groome | CEO, PRESIDENT AND DIRECTOR |
| Jennifer Stewart | DIRECTOR |
| Mark A. Cochran | DIRECTOR |
| Peter M. Blecher | DIRECTOR |
| Vaughn C. Embro-Pantalony | DIRECTOR |
Events
- Next results
- Dec 17, 2026 (expected)
Calls
| Call | When | Status |
|---|---|---|
| Microbix Biosystems (TSX:MBX) Q3 2026 Earnings Call | Thu, Aug 13, 2026 · 10:00 AM ET | Replay |
| Microbix Biosystems (TSX:MBX) Q2 2026 Earnings Call | Thu, May 14, 2026 · 10:00 AM ET | Replay |
| Microbix Biosystems (TSX:MBX) Q1 2026 Earnings Call | Thu, Feb 12, 2026 · 10:00 AM ET | Replay |
| Microbix Biosystems (TSX:MBX) Q4 2025 Earnings Call | Thu, Dec 18, 2025 · 10:00 AM ET | Replay |
| Microbix Biosystems (TSX:MBX) Q3 2025 Earnings Call | Thu, Aug 14, 2025 · 10:00 AM ET | Replay |
| Microbix Biosystems (TSX:MBX) Q2 2025 Earnings Call | Thu, May 15, 2025 · 11:00 AM ET | Replay |
| Microbix Biosystems (TSX:MBX) Q1 2025 Earnings Call | Thu, Feb 13, 2025 · 11:00 AM ET | Replay |
| Microbix Biosystems (TSX:MBX) Q4 2024 Earnings Call | Thu, Dec 19, 2024 · 11:00 AM ET | Replay |
| Microbix Biosystems (TSX:MBX) Q3 2024 Earnings Call | Wed, Aug 14, 2024 · 10:00 AM ET | Replay |
| Microbix Biosystems (TSX:MBX) Q2 2024 Earnings Call | Wed, May 15, 2024 · 10:00 AM ET | Replay |
All 12 calls
| Call | When | Status |
|---|---|---|
| Microbix Biosystems (TSX:MBX) Q4 2023 Earnings Call | Wed, Jan 03, 2024 · 11:00 AM ET | Replay |
| Microbix Biosystems (TSX:MBX) Q3 2023 Earnings Call | Mon, Aug 14, 2023 · 11:00 AM ET | Replay |
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Aug 13, 2026 · Before open | −6.3% |
| Q2 2026 | May 14, 2026 · Before open | −9.8% |
| Q1 2026 | Feb 12, 2026 · Before open | −2.2% |
| Q4 2025 | Dec 18, 2025 · Before open | −12.5% |
| Q3 2025 | Aug 13, 2025 · Before open | −1.8% |
| Q2 2025 | May 15, 2025 · Before open | −5.6% |
| Q1 2025 | Feb 13, 2025 · Before open | 0.0% |
| Q4 2024 | Dec 19, 2024 · Before open | +2.8% |
| Q3 2024 | Aug 14, 2024 · Before open | +3.0% |
| Q2 2024 | May 15, 2024 · Before open | +9.4% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | Feb 14, 2024 · Before open | +6.3% |
| Q4 2023 | Dec 21, 2023 · Before open | −6.7% |
| Q3 2023 | Aug 10, 2023 · Before open | −3.1% |
| Q2 2023 | May 11, 2023 · Before open | 0.0% |
| Q1 2023 | Feb 9, 2023 · Before open | −14.3% |
| Q4 2022 | Dec 22, 2022 · Before open | −5.9% |
| Q3 2022 | Aug 11, 2022 · Before open | +2.0% |
| Q2 2022 | May 12, 2022 · Before open | −3.2% |
| Q1 2022 | Feb 10, 2022 · Before open | +4.6% |
| Q4 2021 | Dec 23, 2021 · Before open | +5.1% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (November 2026) | Investor deck | 28 slides | Nov 17, 2026 |
| Investor Presentation (September 2026) | Investor deck | 24 slides | September 2026 |
| Investor Presentation (August 2026) | Investor deck | 24 slides | Aug 18, 2026 |
| Investor Presentation (September 2025) | Investor deck | 21 slides | Sep 23, 2025 |
| Investor Presentation (August 2025) | Investor deck | 21 slides | August 2025 |
| Investor Presentation (May 2025) | Investor deck | 21 slides | May 15, 2025 |
| Investor Presentation (May 2023) | Investor deck | 23 slides | May 12, 2023 |
| Investor Presentation (November 2022) | Investor deck | 24 slides | Nov 25, 2022 |
| Investor Presentation (September 2022) | Investor deck | 24 slides | Sep 19, 2022 |
| Shareholder Meeting (March 2021) | Shareholder meeting | 20 slides | March 2021 |
All 11 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (May 2014) | Investor deck | 22 slides | May 2014 |
Financials
Annual, in CAD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 18.6M | 25.4M | 16.5M | 19.1M | 18.6M | 10.5M | 13.4M | 12.5M | 10.2M | 9.52M |
| Cost of revenue | 8.73M | 10.0M | 9.03M | 7.95M | 7.55M | 5.86M | 6.86M | 7.14M | 5.37M | 4.54M |
| Gross profit | 9.85M | 15.4M | 7.48M | 11.1M | 11.0M | 4.66M | 6.55M | 5.37M | 4.81M | 4.98M |
| Research and development | 2.33M | 2.13M | 2.05M | 1.80M | 1.03M | 1.01M | 1.04M | 1.09M | 994.6K | 493.6K |
| Selling, general and administrative | 8.76M | 8.63M | 6.53M | 5.00M | 4.22M | 3.54M | 3.74M | 3.61M | 3.93M | 3.13M |
| Operating income | -1.58M | 3.91M | -2.74M | 2.69M | 4.84M | -524.6K | 1.11M | -742.8K | -1.50M | 148.4K |
| Depreciation and amortization | 1.78M | 1.61M | 1.16M | 1.04M | 822.0K | 690.1K | 568.8K | 690.1K | 510.2K | 413.7K |
| EBITDA | 203.2K | 5.52M | -1.58M | 3.73M | 5.66M | 165.5K | 1.68M | -52.7K | -989.4K | 562.1K |
| Interest expense | 950.4K | 921.8K | 839.4K | 826.6K | 1.60M | 1.06M | 1.07M | 852.0K | 924.6K | 691.3K |
| Income before tax | -2.30M | 3.67M | -39.5K | 1.87M | 3.23M | -4.66M | 43.7K | -8.62M | -4.23M | 148.4K |
| Income tax | -55.7K | 150.6K | 839.4K | 77.2K | 1.60M | 1.57M | 11.8K | -7.03M | -450.0K | -600.0K |
| Net income | -2.25M | 3.52M | -39.5K | 1.79M | 1.63M | -6.23M | 31.9K | -8.62M | -3.78M | 748.4K |
| Earnings per share, basic | -0.02 | 0.03 | -0.00 | 0.01 | 0.01 | -0.06 | 0.00 | -0.09 | -0.04 | 0.01 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 12.1M | 13.0M | 11.6M | 13.5M | 9.99M | 92.7K | 95.6K | 44.4K | 54.5K | 5.42K |
| Receivables | 1.61M | 4.19M | 4.18M | 3.09M | 4.21M | 1.89M | 1.71M | 1.41M | 1.49M | 2.20M |
| Inventory | 9.20M | 6.46M | 5.75M | 5.28M | 4.41M | 4.29M | 4.48M | 4.45M | 4.47M | 3.40M |
| Current assets | 23.6M | 24.3M | 22.3M | 22.4M | 19.1M | 6.49M | 6.45M | 6.07M | 6.16M | 5.66M |
| Property, plant and equipment | 10.1M | 9.62M | 8.93M | 8.91M | 8.08M | 7.36M | 6.65M | 6.65M | 12.2M | 12.3M |
| Total assets | 37.4M | 38.1M | 35.7M | 33.1M | 28.8M | 15.6M | 19.6M | 19.3M | 26.4M | 25.2M |
| Accounts payable | 1.98M | 2.66M | 2.08M | 1.83M | 1.79M | 1.49M | 1.46M | 1.77M | 2.84M | 1.90M |
| Current liabilities | 2.78M | 3.39M | 4.35M | 2.65M | 5.19M | 4.09M | 4.77M | 4.16M | 6.52M | 5.25M |
| Long-term debt | 5.26M | 5.59M | 5.68M | 4.71M | 4.09M | 4.51M | 4.16M | 4.55M | 4.67M | 4.70M |
| Total debt | 6.77M | 6.40M | 6.65M | 5.82M | 7.74M | 6.17M | 6.99M | 6.26M | 7.28M | 7.37M |
| Total liabilities | 9.62M | 9.80M | 11.0M | 8.21M | 10.3M | 8.98M | 9.09M | 8.96M | 11.3M | 9.96M |
| Shareholders' equity | 27.8M | 28.3M | 24.6M | 24.9M | 18.6M | 6.62M | 10.5M | 10.4M | 15.2M | 15.3M |
| Shares outstanding | 139.2M | 137.5M | 137.9M | 141.7M | 141.7M | 104.8M | 97.1M | 96.2M | 85.0M | 84.7M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -80.3K | 4.35M | -1.09M | 3.47M | 2.11M | 8.57K | 44.4K | -537.0K | 297.0K | 913.3K |
| Capital spending | -797.3K | -1.91M | -1.02M | -2.03M | -1.30M | -813.9K | -514.8K | -1.22M | -640.8K | -1.64M |
| Free cash flow | -877.6K | 2.44M | -2.11M | 1.44M | 804.2K | -805.3K | -470.4K | -1.76M | -343.7K | -727.8K |
| Cash from investing | -797.3K | -1.91M | -1.02M | -2.03M | -622.3K | -813.9K | -514.8K | -1.22M | -640.8K | -1.64M |
| Cash from financing | 27.0K | -1.08M | 229.2K | 2.06M | 8.41M | 802.4K | 521.6K | 1.74M | 392.7K | 629.1K |
| Share buybacks | -1.73M | -925.3K | -1.12M | 3.44M | 8.33M | 2.15M | 0 | 3.24M | 0 | 531.7K |
| Change in cash | -850.6K | 1.36M | -1.88M | 3.50M | 9.89M | -2.91K | 51.2K | -10.1K | 49.0K | -98.8K |
Cap table
Built by 6ix from Microbix Biosystems Inc.’s releases
- Common shares
- 136,968,656
- Fully diluted
- 136,968,656
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 136,968,656 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 136,968,656 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Cameron Groome | CEO, PRESIDENT AND DIRECTOR · Since at least Nov 2, 2026 |
| Deborah Honig | Investor Relations · Since at least Nov 2, 2026 |
| Jennifer Stewart | DIRECTOR · Since at least Mar 26, 2026 |
| Jim Currie | CFO · Since at least Nov 2, 2026 |
| Joe Renner | Until Nov 2, 2026 · Past |
| Ken Hughes | COO · Since at least Apr 16, 2026 |
| Mark A. Cochran | DIRECTOR · Since at least Mar 26, 2026 |
| Mark Luscher | SVP, SCIENTIFIC AFFAIRS · Since at least Oct 8, 2026 |
| Martin Marino | CHAIRMAN OF THE BOARD · Since at least Mar 26, 2026 |
| Peter M. Blecher | DIRECTOR · Since at least Mar 26, 2026 |
All 12 people
| Person | Seat |
|---|---|
| Phil Casselli | SVP BUSINESS DEVELOPMENT, SALES AND MARKETING · Since at least Dec 3, 2025 |
| Vaughn C. Embro-Pantalony | DIRECTOR · Since at least Mar 26, 2026 |
Log in to ask 6ix AI your own questions about Microbix Biosystems Inc.